Inhibition of human alpha1E subunit-mediated ca2+ channels by the antipsychotic agent chlorpromazine

Acta Physiologica Scandinavica
Nicolle C L McNaughtonAndrew Randall

Abstract

Chlorpromazine is a neuroleptic antipsychotic agent with a long history of clinical use. Its primary mode of action is thought to be through modulation of monoaminergic inter-neuronal communication; however, its side-effect profile indicates substantial activities in other systems. Recent work has begun to uncover actions of this compound on ion channels. In this light we have investigated the actions of chlorpromazine on the recombinant alpha1E subunit-encoded voltage-sensitive Ca2+ channel (VSCC) that is believed to encode drug-resistant R-type currents found in neurones and other cells. Chlorpromazine produced a dose-dependent antagonism of these channels that was reversed on drug removal. The mean IC50 was close to 10 microM. At this concentration, the level of antagonism observed was dependent on the membrane potential, with greater inhibition being observed at more negative test potentials. Furthermore, chlorpromazine induced substantial changes in the steady-state inactivation properties of alpha1Ebeta3-mediated currents, although it was not seen to elicit a corresponding change in inactivation kinetics. These results are discussed with regard to the possible clinical mechanisms of chlorpromazine actions.

References

Jul 1, 1975·Contraception·J Lippes
May 30, 1991·European Journal of Pharmacology·M MüllerM Lazdunski
Sep 1, 1970·The Journal of Pharmacy and Pharmacology·A L Green
Mar 1, 1981·British Journal of Pharmacology·J S de Belleroche, H F Bradford
Mar 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·T Heidmann, J P Changeux
Feb 21, 1997·Biochimica Et Biophysica Acta·G A Quamme
Apr 1, 1997·Journal of Neurophysiology·S W Jeong, R D Wurster
Aug 1, 1997·Brain Research·T I LidskyS P Banerjee
Mar 1, 1996·Harvard Review of Psychiatry·R J Baldessarini, F I Tarazi
May 16, 1998·Proceedings of the National Academy of Sciences of the United States of America·L G WuB Sakmann
Jun 24, 1998·Proceedings of the National Academy of Sciences of the United States of America·E S Piedras-Rentería, R W Tsien
Jul 31, 1998·Progress in Neuro-psychopharmacology & Biological Psychiatry·F I TaraziR J Baldessarini
Apr 14, 1999·Journal of Neurophysiology·P KriegerA el Manira
Jun 24, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·K M Hemsley, A D Crocker
Jul 29, 1999·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·H GrabschT Schneider
Dec 1, 1999·Comprehensive Psychiatry·W W Shen
Apr 1, 2000·The Journal of Biological Chemistry·F MaingretE Honoré

❮ Previous
Next ❯

Citations

Oct 30, 2016·Proceedings of the National Academy of Sciences of the United States of America·Mieke NysChris Ulens
Apr 24, 2014·European Journal of Pharmacology·Hua-Juan LiZhi Qi
Apr 29, 2020·Doklady. Biochemistry and Biophysics·Z I KrutetskayaA D Nozdrachev

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here